+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Genome Editing Market Size, Share & Trends Analysis Report by Technology (CRISPR/Cas9, ZFN), Delivery Method (Ex-vivo, In-vivo), Application, Mode, End-use, Region, and Segment Forecasts, 2024-2030

  • PDF Icon

    Report

  • 120 Pages
  • May 2024
  • Region: Global
  • Grand View Research
  • ID: 4751813
The global genome editing market size is expected to reach USD 25.00 billion by 2030, exhibiting a CAGR of 16.94% from 2024 to 2030. The increasing advancements in genome editing technology, the growing funding & investments in the genomics industry, the increasing prevalence of genetic disorders, and the need for improved treatments and therapies are major factors driving revenue growth.

The evolution of genome editing technologies is another contributing factor to drive revenue growth in the market. Most effective and accurate gene editing is now possible through the enhancement of new and advanced genome editing methods including CRISPR-Cas13,prime editing, and base editing, amongst others. This creates genome editing methods used more often in academic and medical contexts. For instance, in January 2020, ERS Genomics and New England Biolab collaborated to develop and commercialize CRISPR gene modification tools & reagents.

The increasing application of gene-modification tools in therapeutic research has resulted in the rising number of advanced therapeutics entering clinical trials. Furthermore, the use of artificial intelligence to advance the implementation of novel gene modification systems exhibits great potential for the technology developer. This is anticipated to greatly favor revenue generation in the foreseeable future. Research communities are exploring the potential of gene-modification instruments such as CRISPR as a potential fast screening solution for various chronic diseases. Such research programs are likely to benefit the market for genome editing in the coming years.

Genome Editing Market Report Highlights

  • By technology, The CRISPR/Cas9 segment held the largest market share of 43.52% of the global revenue in 2023.
  • The ex-vivo segment dominated the market with a share of 51.24% in 2023. This dominance can be attributed to the ease of control in DNA modification provided along with the precise regulation of strength and duration of nuclease expression to minimize off-target editing and maximize efficiency.
  • The genetic engineering segment held the largest market share in 2023. The segment is further categorized into cell line engineering, animal genetic engineering, plant genetic engineering, and others.
  • The contract segment dominated the market in 2023 due to the high extent of outsourcing activities in the genomics space driven by the lower costs and greater flexibility in operations offered by such activities as compared to in-house development.
  • The biotechnology and pharmaceutical companies segment accounted for the largest market share of 50.95% in 2023.
  • North America dominated the market and accounted for a 47.81% share in 2023 owing to the growing investments in the R&D of gene editing technologies.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Technology Segment
1.2.2. Delivery Method Segment
1.2.3. Application Segment
1.2.4. Mode Segment
1.2.5. End-use Segment
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Information or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity Flow Analysis (Model 1)
1.7.2. Approach 1: Commodity Flow Approach
1.7.3. Volume Price Analysis (Model 2)
1.7.4. Approach 2: Volume Price Analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
1.10.1. Objective 1
1.10.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Insights Landscape
Chapter 3. Genome Editing Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/ancillary Market Outlook.
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Success in Pre-clinical Models Drives Demand for Genome Editing Therapeutics
3.2.1.2. Rising Competition Amongst Market Participants for Business Development
3.2.1.3. Easy Editing Solutions for the Development of Therapeutics for a Broad Range of Diseases
3.2.1.4. Increasing Demand for Synthetic Genes and Genetically Modified Organisms
3.2.1.5. Technological Advancements in Gene Editing Technologies
3.2.1.6. Rising Adoption in Agricultural Biotechnology
3.2.2. Market Restraint Analysis
3.2.2.1. Challenges Concerning Clinical Translation
3.2.2.2. Regulatory, Scientific, and Ethical Challenges Regarding the Use of Genetically Modified Products
3.2.2.3. Off-target Effects of CRISPR Technology
3.3. Genome Editing Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. Genome Editing Market: Technology Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Global Genome Editing Market Technology Movement Analysis
4.3. Global Genome Editing Market Size & Trend Analysis, by Technology, 2018 to 2030 (USD Million)
4.4. (CRISPR)/Cas9
4.4.1. (CRISPR)/Cas9 Market Estimates and Forecasts 2018 to 2030 (USD Million)
4.5. TALENs/MegaTALs
4.5.1. TALENs/MegaTALs Market Estimates and Forecasts 2018 to 2030 (USD Million)
4.6. ZFN
4.6.1. ZFN Market Estimates and Forecasts 2018 to 2030 (USD Million)
4.7. Meganuclease
4.7.1. Meganuclease Market Estimates and Forecasts 2018 to 2030 (USD Million)
4.8. Others
4.8.1. Others Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 5. Genome Editing Market: Delivery Method Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Global Genome Editing Market Delivery Method Movement Analysis
5.3. Global Genome Editing Market Size & Trend Analysis, by Delivery Method, 2018 to 2030 (USD Million)
5.4. Ex-vivo
5.4.1. Ex-vivo Market Estimates and Forecasts 2018 to 2030 (USD Million)
5.5. In-Vivo
5.5.1. In-vivo Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 6. Genome Editing Market: Application Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Global Genome Editing Market Application Movement Analysis
6.3. Global Genome Editing Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
6.4. Genetic Engineering
6.4.1. Genetic Engineering Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.4.2. Cell Line Engineering
6.4.2.1. Cell Line Engineering Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.4.3. Animal Genetic Engineering
6.4.3.1. Animal Genetic Engineering Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.4.4. Plant Genetic Engineering
6.4.4.1. Plant Genetic Engineering Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.4.5. Others
6.4.5.1. Others Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.5. Clinical Applications
6.5.1. Clinical Applications Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.5.2. Diagnostics
6.5.2.1. Diagnostics Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.5.3. Therapy Development
6.5.3.1. Therapy Development Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 7. Genome Editing Market: Mode Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. Global Genome Editing Market Mode Movement Analysis
7.3. Global Genome Editing Market Size & Trend Analysis, by Mode, 2018 to 2030 (USD Million)
7.4. Contract
7.4.1. Contract Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.5. In-house
7.5.1. In-house Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 8. Genome Editing Market: End-use Estimates & Trend Analysis
8.1. Segment Dashboard
8.2. Global Genome Editing Market End-use Movement Analysis
8.3. Global Genome Editing Market Size & Trend Analysis, by End-Use, 2018 to 2030 (USD Million)
8.4. Biotechnology and Pharmaceutical Companies
8.4.1. Biotechnology and Pharmaceutical Companies Market Estimates and Forecasts 2018 to 2030 (USD Million)
8.5. Academic and Government Research Institutes
8.5.1. Academic and Government Research Institutes Market Estimates and Forecasts 2018 to 2030 (USD Million)
8.6. Contract Research Organizations
8.6.1. Contract Research Organizations Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 9. Genome Editing Market: Regional Estimates & Trend Analysis
9.1. Regional Market Share Analysis, 2023 & 2030
9.2. Regional Market Dashboard
9.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
9.4. North America
9.4.1. U.S.
9.4.1.1. Key Country Dynamics
9.4.1.2. Regulatory Framework
9.4.1.3. Target Disease Prevalence
9.4.1.4. Competitive Scenario
9.4.1.5. U.S. Market Estimates and Forecasts 2018 to 2030 (USD Million)
9.4.2. Canada
9.4.2.1. Key Country Dynamics
9.4.2.2. Regulatory Framework
9.4.2.3. Target Disease Prevalence
9.4.2.4. Competitive Scenario
9.4.2.5. Canada Market Estimates and Forecasts 2018 to 2030 (USD Million)
9.5. Europe
9.5.1. UK
9.5.1.1. Key Country Dynamics
9.5.1.2. Regulatory Framework
9.5.1.3. Target Disease Prevalence
9.5.1.4. Competitive Scenario
9.5.1.5. UK Market Estimates and Forecasts 2018 to 2030 (USD Million)
9.5.2. Germany
9.5.2.1. Key Country Dynamics
9.5.2.2. Regulatory Framework
9.5.2.3. Target Disease Prevalence
9.5.2.4. Competitive Scenario
9.5.2.5. Germany Market Estimates and Forecasts 2018 to 2030 (USD Million)
9.5.3. France
9.5.3.1. Key Country Dynamics
9.5.3.2. Regulatory Framework
9.5.3.3. Target Disease Prevalence
9.5.3.4. Competitive Scenario
9.5.3.5. France Market Estimates and Forecasts 2018 to 2030 (USD Million)
9.5.4. Italy
9.5.4.1. Key Country Dynamics
9.5.4.2. Regulatory Framework
9.5.4.3. Target Disease Prevalence
9.5.4.4. Competitive Scenario
9.5.4.5. Italy Market Estimates and Forecasts 2018 to 2030 (USD Million)
9.5.5. Spain
9.5.5.1. Key Country Dynamics
9.5.5.2. Regulatory Framework
9.5.5.3. Target Disease Prevalence
9.5.5.4. Competitive Scenario
9.5.5.5. Spain Market Estimates and Forecasts 2018 to 2030 (USD Million)
9.5.6. Norway
9.5.6.1. Key Country Dynamics
9.5.6.2. Regulatory Framework
9.5.6.3. Target Disease Prevalence
9.5.6.4. Competitive Scenario
9.5.6.5. Norway Market Estimates and Forecasts 2018 to 2030 (USD Million)
9.5.7. Sweden
9.5.7.1. Key Country Dynamics
9.5.7.2. Target Disease Prevalence
9.5.7.3. Regulatory Framework
9.5.7.4. Competitive Scenario
9.5.7.5. Sweden Market Estimates and Forecasts 2018 to 2030 (USD Million)
9.5.8. Denmark
9.5.8.1. Key Country Dynamics
9.5.8.2. Regulatory Framework
9.5.8.3. Target Disease Prevalence
9.5.8.4. Competitive Scenario
9.5.8.5. Denmark Market Estimates and Forecasts 2018 to 2030 (USD Million)
9.6. Asia-Pacific
9.6.1. Japan
9.6.1.1. Key Country Dynamics
9.6.1.2. Regulatory Framework
9.6.1.3. Target Disease Prevalence
9.6.1.4. Competitive Scenario
9.6.1.5. Japan Market Estimates and Forecasts 2018 to 2030 (USD Million)
9.6.2. China
9.6.2.1. Key Country Dynamics
9.6.2.2. Regulatory Framework
9.6.2.3. Target Disease Prevalence
9.6.2.4. Competitive Scenario
9.6.2.5. China Market Estimates and Forecasts 2018 to 2030 (USD Million)
9.6.3. India
9.6.3.1. Key Country Dynamics
9.6.3.2. Regulatory Framework
9.6.3.3. Competitive Scenario
9.6.3.4. Target Disease Prevalence
9.6.3.5. India Market Estimates and Forecasts 2018 to 2030 (USD Million)
9.6.4. Australia
9.6.4.1. Key Country Dynamics
9.6.4.2. Regulatory Framework
9.6.4.3. Target Disease Prevalence
9.6.4.4. Competitive Scenario
9.6.4.5. Australia Market Estimates and Forecasts 2018 to 2030 (USD Million)
9.6.5. South Korea
9.6.5.1. Key Country Dynamics
9.6.5.2. Regulatory Framework
9.6.5.3. Target Disease Prevalence
9.6.5.4. Competitive Scenario
9.6.5.5. South Korea Market Estimates and Forecasts 2018 to 2030 (USD Million)
9.6.6. Thailand
9.6.6.1. Key Country Dynamics
9.6.6.2. Target Disease Prevalence
9.6.6.3. Regulatory Framework
9.6.6.4. Competitive Scenario
9.6.6.5. Thailand Market Estimates and Forecasts 2018 to 2030 (USD Million)
9.7. Latin America
9.7.1. Brazil
9.7.1.1. Key Country Dynamics
9.7.1.2. Regulatory Framework
9.7.1.3. Target Disease Prevalence
9.7.1.4. Competitive Scenario
9.7.1.5. Brazil Market Estimates and Forecasts 2018 to 2030 (USD Million)
9.7.2. Mexico
9.7.2.1. Key Country Dynamics
9.7.2.2. Regulatory Framework
9.7.2.3. Target Disease Prevalence
9.7.2.4. Competitive Scenario
9.7.2.5. Mexico Market Estimates and Forecasts 2018 to 2030 (USD Million)
9.7.3. Argentina
9.7.3.1. Key Country Dynamics
9.7.3.2. Regulatory Framework
9.7.3.3. Target Disease Prevalence
9.7.3.4. Competitive Scenario
9.7.3.5. Argentina Market Estimates and Forecasts 2018 to 2030 (USD Million)
9.8. MEA
9.8.1. South Africa
9.8.1.1. Key Country Dynamics
9.8.1.2. Regulatory Framework
9.8.1.3. Competitive Scenario
9.8.1.4. Target Disease Prevalence
9.8.1.5. South Africa Market Estimates and Forecasts 2018 to 2030 (USD Million)
9.8.2. Saudi Arabia
9.8.2.1. Key Country Dynamics
9.8.2.2. Regulatory Framework
9.8.2.3. Target Disease Prevalence
9.8.2.4. Competitive Scenario
9.8.2.5. Saudi Arabia Market Estimates and Forecasts 2018 to 2030 (USD Million)
9.8.3. UAE
9.8.3.1. Key Country Dynamics
9.8.3.2. Regulatory Framework
9.8.3.3. Target Disease Prevalence
9.8.3.4. Competitive Scenario
9.8.3.5. UAE Market Estimates and Forecasts 2018 to 2030 (USD Million)
9.8.4. Kuwait
9.8.4.1. Key Country Dynamics
9.8.4.2. Regulatory Framework
9.8.4.3. Target Disease Prevalence
9.8.4.4. Competitive Scenario
9.8.4.5. Kuwait Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 10. Competitive Landscape
10.1. Company/Competition Categorization
10.2. Strategy Mapping
10.3. Company Market Position Analysis, 2023
10.4. Company Profiles/Listing
10.4.1. Merck KGaA
10.4.1.1. Company Overview
10.4.1.2. Financial Performance
10.4.1.3. Product Benchmarking
10.4.1.4. Strategic Initiatives
10.4.2. Cibus Inc
10.4.2.1. Company Overview
10.4.2.2. Financial Performance
10.4.2.3. Product Benchmarking
10.4.2.4. Strategic Initiatives
10.4.3. Recombinetics
10.4.3.1. Company Overview
10.4.3.2. Financial Performance
10.4.3.3. Product Benchmarking
10.4.3.4. Strategic Initiatives
10.4.4. Sangamo Therapeutics
10.4.4.1. Company Overview
10.4.4.2. Financial Performance
10.4.4.3. Product Benchmarking
10.4.4.4. Strategic Initiatives
10.4.5. Editas Medicine
10.4.5.1. Company Overview
10.4.5.2. Financial Performance
10.4.5.3. Product Benchmarking
10.4.5.4. Strategic Initiatives
10.4.6. Precision BioSciences
10.4.6.1. Company Overview
10.4.6.2. Financial Performance
10.4.6.3. Product Benchmarking
10.4.6.4. Strategic Initiatives
10.4.7. CRISPR Therapeutics
10.4.7.1. Company Overview
10.4.7.2. Financial Performance
10.4.7.3. Product Benchmarking
10.4.7.4. Strategic Initiatives
10.4.8. Intellia Therapeutics, Inc
10.4.8.1. Company Overview
10.4.8.2. Financial Performance
10.4.8.3. Product Benchmarking
10.4.8.4. Strategic Initiatives
10.4.9. Caribou Biosciences, Inc.
10.4.9.1. Company Overview
10.4.9.2. Financial Performance
10.4.9.3. Product Benchmarking
10.4.9.4. Strategic Initiatives
10.4.10. Cellectis S.A
10.4.10.1. Company Overview
10.4.10.2. Financial Performance
10.4.10.3. Product Benchmarking
10.4.10.4. Strategic Initiatives
10.4.11. AstraZeneca
10.4.11.1. Company Overview
10.4.11.2. Financial Performance
10.4.11.3. Product Benchmarking
10.4.11.4. Strategic Initiatives
10.4.12. Takara Bio Inc.
10.4.12.1. Company Overview
10.4.12.2. Financial Performance
10.4.12.3. Product Benchmarking
10.4.12.4. Strategic Initiatives
10.4.13. Horizon Discovery Ltd. (Revvity, Inc.)
10.4.13.1. Company Overview
10.4.13.2. Financial Performance
10.4.13.3. Product Benchmarking
10.4.13.4. Strategic Initiatives
10.4.14. Danaher Corporation
10.4.14.1. Company Overview
10.4.14.2. Financial Performance
10.4.14.3. Product Benchmarking
10.4.14.4. Strategic Initiatives
10.4.15. Transposagen Biopharmaceuticals, Inc.
10.4.15.1. Company Overview
10.4.15.2. Financial Performance
10.4.15.3. Product Benchmarking
10.4.15.4. Strategic Initiatives
10.4.16. Genscript Biotech Corp
10.4.16.1. Company Overview
10.4.16.2. Financial Performance
10.4.16.3. Product Benchmarking
10.4.16.4. Strategic Initiatives
10.4.17. New England Biolabs
10.4.17.1. Company Overview
10.4.17.2. Financial Performance
10.4.17.3. Product Benchmarking
10.4.17.4. Strategic Initiatives
10.4.18. OriGene Technologies, Inc.
10.4.18.1. Company Overview
10.4.18.2. Financial Performance
10.4.18.3. Product Benchmarking
10.4.18.4. Strategic Initiatives
10.4.19. Bluebird Bio, Inc
10.4.19.1. Company Overview
10.4.19.2. Financial Performance
10.4.19.3. Product Benchmarking
10.4.19.4. Strategic Initiatives
10.4.20. Lonza
10.4.20.1. Company Overview
10.4.20.2. Financial Performance
10.4.20.3. Product Benchmarking
10.4.20.4. Strategic Initiatives
10.4.21. Thermo Fisher Scientific, Inc.
10.4.21.1. Company Overview
10.4.21.2. Financial Performance
10.4.21.3. Product Benchmarking
10.4.21.4. Strategic Initiatives
List of Tables
Table 1 List of Abbreviation
Table 2 Global Genome Editing Market, by Region, 2018-2030 (USD Million)
Table 3 Global Genome Editing Market, by Technology, 2018-2030 (USD Million)
Table 4 Global Genome Editing Market, by Delivery Method, 2018-2030 (USD Million)
Table 5 Global Genome Editing Market, by Application, 2018-2030 (USD Million)
Table 6 Global Genome Editing Market, for Genetic Engineering, by Application, 2018-2030 (USD Million)
Table 7 Global Genome Editing Market, for Clinical Applications, by Application, 2018-2030 (USD Million)
Table 8 Global Genome Editing Market, by Mode, 2018-2030 (USD Million)
Table 9 Global Genome Editing Market, by End-use, 2018-2030 (USD Million)
Table 10 North America Genome Editing Market, by Country, 2018-2030 (USD Million)
Table 11 North America Genome Editing Market, by Technology, 2018-2030 (USD Million)
Table 12 North America Genome Editing Market, by Delivery Method, 2018-2030 (USD Million)
Table 13 North America Genome Editing Market, by Application, 2018-2030 (USD Million)
Table 14 North America Genome Editing Market, for Genetic Engineering, by Application, 2018-2030 (USD Million)
Table 15 North America Genome Editing Market, for Clinical Applications, by Application, 2018-2030 (USD Million)
Table 16 North America Genome Editing Market, by Mode, 2018-2030 (USD Million)
Table 17 North America Genome Editing Market, by End-use, 2018-2030 (USD Million)
Table 18 U.S. Genome Editing Market, by Technology, 2018-2030 (USD Million)
Table 19 U.S. Genome Editing Market, by Delivery Method, 2018-2030 (USD Million)
Table 20 U.S. Genome Editing Market, by Application, 2018-2030 (USD Million)
Table 21 U.S. Genome Editing Market, for Genetic Engineering, by Application, 2018-2030 (USD Million)
Table 22 U.S. Genome Editing Market, for Clinical Applications, by Application, 2018-2030 (USD Million)
Table 23 U.S. Genome Editing Market, by Mode, 2018-2030 (USD Million)
Table 24 U.S. Genome Editing Market, by End-use, 2018-2030 (USD Million)
Table 25 Canada Genome Editing Market, by Technology, 2018-2030 (USD Million)
Table 26 Canada Genome Editing Market, by Delivery Method, 2018-2030 (USD Million)
Table 27 Canada Genome Editing Market, by Application, 2018-2030 (USD Million)
Table 28 Canada Genome Editing Market, for Genetic Engineering, by Application, 2018-2030 (USD Million)
Table 29 Canada Genome Editing Market, for Clinical Applications, by Application, 2018-2030 (USD Million)
Table 30 Canada Genome Editing Market, by Mode, 2018-2030 (USD Million)
Table 31 Canada Genome Editing Market, by End-use, 2018-2030 (USD Million)
Table 32 Europe Genome Editing Market, by Country, 2018-2030 (USD Million)
Table 33 Europe Genome Editing Market, by Technology, 2018-2030 (USD Million)
Table 34 Europe Genome Editing Market, by Delivery Method, 2018-2030 (USD Million)
Table 35 Europe Genome Editing Market, by Application, 2018-2030 (USD Million)
Table 36 Europe Genome Editing Market, for Genetic Engineering, by Application, 2018-2030 (USD Million)
Table 37 Europe Genome Editing Market, for Clinical Applications, by Application, 2018-2030 (USD Million)
Table 38 Europe Genome Editing Market, by Mode, 2018-2030 (USD Million)
Table 39 Europe Genome Editing Market, by End-use, 2018-2030 (USD Million)
Table 40 Germany Genome Editing Market, by Technology, 2018-2030 (USD Million)
Table 41 Germany Genome Editing Market, by Delivery Method, 2018-2030 (USD Million)
Table 42 Germany Genome Editing Market, by Application, 2018-2030 (USD Million)
Table 43 Germany Genome Editing Market, for Genetic Engineering, by Application, 2018-2030 (USD Million)
Table 44 Germany Genome Editing Market, for Clinical Applications, by Application, 2018-2030 (USD Million)
Table 45 Germany Genome Editing Market, by Mode, 2018-2030 (USD Million)
Table 46 Germany Genome Editing Market, by End-use, 2018-2030 (USD Million)
Table 47 UK Genome Editing Market, by Technology, 2018-2030 (USD Million)
Table 48 UK Genome Editing Market, by Delivery Method, 2018-2030 (USD Million)
Table 49 UK Genome Editing Market, by Application, 2018-2030 (USD Million)
Table 50 UK Genome Editing Market, for Genetic Engineering, by Application, 2018-2030 (USD Million)
Table 51 UK Genome Editing Market, for Clinical Applications, by Application, 2018-2030 (USD Million)
Table 52 UK Genome Editing Market, by Mode, 2018-2030 (USD Million)
Table 53 UK Genome Editing Market, by End-use, 2018-2030 (USD Million)
Table 54 France Genome Editing Market, by Technology, 2018-2030 (USD Million)
Table 55 France Genome Editing Market, by Delivery Method, 2018-2030 (USD Million)
Table 56 France Genome Editing Market, by Application, 2018-2030 (USD Million)
Table 57 France Genome Editing Market, for Genetic Engineering, by Application, 2018-2030 (USD Million)
Table 58 France Genome Editing Market, for Clinical Applications, by Application, 2018-2030 (USD Million)
Table 59 France Genome Editing Market, by Mode, 2018-2030 (USD Million)
Table 60 France Genome Editing Market, by End-use, 2018-2030 (USD Million)
Table 61 Italy Genome Editing Market, by Technology, 2018-2030 (USD Million)
Table 62 Italy Genome Editing Market, by Delivery Method, 2018-2030 (USD Million)
Table 63 Italy Genome Editing Market, by Application, 2018-2030 (USD Million)
Table 64 Italy Genome Editing Market, for Genetic Engineering, by Application, 2018-2030 (USD Million)
Table 65 Italy Genome Editing Market, for Clinical Applications, by Application, 2018-2030 (USD Million)
Table 66 Italy Genome Editing Market, by Mode, 2018-2030 (USD Million)
Table 67 Italy Genome Editing Market, by End-use, 2018-2030 (USD Million)
Table 68 Spain Genome Editing Market, by Technology, 2018-2030 (USD Million)
Table 69 Spain Genome Editing Market, by Delivery Method, 2018-2030 (USD Million)
Table 70 Spain Genome Editing Market, by Application, 2018-2030 (USD Million)
Table 71 Spain Genome Editing Market, for Genetic Engineering, by Application, 2018-2030 (USD Million)
Table 72 Spain Genome Editing Market, for Clinical Applications, by Application, 2018-2030 (USD Million)
Table 73 Spain Genome Editing Market, by Mode, 2018-2030 (USD Million)
Table 74 Spain Genome Editing Market, by End-use, 2018-2030 (USD Million)
Table 75 Denmark Genome Editing Market, by Technology, 2018-2030 (USD Million)
Table 76 Denmark Genome Editing Market, by Delivery Method, 2018-2030 (USD Million)
Table 77 Denmark Genome Editing Market, by Application, 2018-2030 (USD Million)
Table 78 Denmark Genome Editing Market, for Genetic Engineering, by Application, 2018-2030 (USD Million)
Table 79 Denmark Genome Editing Market, for Clinical Applications, by Application, 2018-2030 (USD Million)
Table 80 Denmark Genome Editing Market, by Mode, 2018-2030 (USD Million)
Table 81 Denmark Genome Editing Market, by End-use, 2018-2030 (USD Million)
Table 82 Sweden Genome Editing Market, by Technology, 2018-2030 (USD Million)
Table 83 Sweden Genome Editing Market, by Delivery Method, 2018-2030 (USD Million)
Table 84 Sweden Genome Editing Market, by Application, 2018-2030 (USD Million)
Table 85 Sweden Genome Editing Market, for Genetic Engineering, by Application, 2018-2030 (USD Million)
Table 86 Sweden Genome Editing Market, for Clinical Applications, by Application, 2018-2030 (USD Million)
Table 87 Sweden Genome Editing Market, by Mode, 2018-2030 (USD Million)
Table 88 Sweden Genome Editing Market, by End-use, 2018-2030 (USD Million)
Table 89 Norway Genome Editing Market, by Technology, 2018-2030 (USD Million)
Table 90 Norway Genome Editing Market, by Delivery Method, 2018-2030 (USD Million)
Table 91 Norway Genome Editing Market, by Application, 2018-2030 (USD Million)
Table 92 Norway Genome Editing Market, for Genetic Engineering, by Application, 2018-2030 (USD Million)
Table 93 Norway Genome Editing Market, for Clinical Applications, by Application, 2018-2030 (USD Million)
Table 94 Norway Genome Editing Market, by Mode, 2018-2030 (USD Million)
Table 95 Norway Genome Editing Market, by End-use, 2018-2030 (USD Million)
Table 96 Asia-Pacific Genome Editing Market, by Country, 2018-2030 (USD Million)
Table 97 Asia-Pacific Genome Editing Market, by Technology, 2018-2030 (USD Million)
Table 98 Asia-Pacific Genome Editing Market, by Delivery Method, 2018-2030 (USD Million)
Table 99 Asia-Pacific Genome Editing Market, by Application, 2018-2030 (USD Million)
Table 100 Asia-Pacific Genome Editing Market, for Genetic Engineering, by Application, 2018-2030 (USD Million)
Table 101 Asia-Pacific Genome Editing Market, for Clinical Applications, by Application, 2018-2030 (USD Million)
Table 102 Asia-Pacific Genome Editing Market, by Mode, 2018-2030 (USD Million)
Table 103 Asia-Pacific Genome Editing Market, by End-use, 2018-2030 (USD Million)
Table 104 China Genome Editing Market, by Technology, 2018-2030 (USD Million)
Table 105 China Genome Editing Market, by Delivery Method, 2018-2030 (USD Million)
Table 106 China Genome Editing Market, by Application, 2018-2030 (USD Million)
Table 107 China Genome Editing Market, for Genetic Engineering, by Application, 2018-2030 (USD Million)
Table 108 China Genome Editing Market, for Clinical Applications, by Application, 2018-2030 (USD Million)
Table 109 China Genome Editing Market, by Mode, 2018-2030 (USD Million)
Table 110 China Genome Editing Market, by End-use, 2018-2030 (USD Million)
Table 111 Japan Genome Editing Market, by Technology, 2018-2030 (USD Million)
Table 112 Japan Genome Editing Market, by Delivery Method, 2018-2030 (USD Million)
Table 113 Japan Genome Editing Market, by Application, 2018-2030 (USD Million)
Table 114 Japan Genome Editing Market, for Genetic Engineering, by Application, 2018-2030 (USD Million)
Table 115 Japan Genome Editing Market, for Clinical Applications, by Application, 2018-2030 (USD Million)
Table 116 Japan Genome Editing Market, by Mode, 2018-2030 (USD Million)
Table 117 Japan Genome Editing Market, by End-use, 2018-2030 (USD Million)
Table 118 India Genome Editing Market, by Technology, 2018-2030 (USD Million)
Table 119 India Genome Editing Market, by Delivery Method, 2018-2030 (USD Million)
Table 120 India Genome Editing Market, by Application, 2018-2030 (USD Million)
Table 121 India Genome Editing Market, for Genetic Engineering, by Application, 2018-2030 (USD Million)
Table 122 India Genome Editing Market, for Clinical Applications, by Application, 2018-2030 (USD Million)
Table 123 India Genome Editing Market, by Mode, 2018-2030 (USD Million)
Table 124 India Genome Editing Market, by End-use, 2018-2030 (USD Million)
Table 125 South Korea Genome Editing Market, by Technology, 2018-2030 (USD Million)
Table 126 South Korea Genome Editing Market, by Delivery Method, 2018-2030 (USD Million)
Table 127 South Korea Genome Editing Market, by Application, 2018-2030 (USD Million)
Table 128 South Korea Genome Editing Market, for Genetic Engineering, by Application, 2018-2030 (USD Million)
Table 129 South Korea Genome Editing Market, for Clinical Applications, by Application, 2018-2030 (USD Million)
Table 130 South Korea Genome Editing Market, by Mode, 2018-2030 (USD Million)
Table 131 South Korea Genome Editing Market, by End-use, 2018-2030 (USD Million)
Table 132 Australia Genome Editing Market, by Technology, 2018-2030 (USD Million)
Table 133 Australia Genome Editing Market, by Delivery Method, 2018-2030 (USD Million)
Table 134 Australia Genome Editing Market, by Application, 2018-2030 (USD Million)
Table 135 Australia Genome Editing Market, for Genetic Engineering, by Application, 2018-2030 (USD Million)
Table 136 Australia Genome Editing Market, for Clinical Applications, by Application, 2018-2030 (USD Million)
Table 137 Australia Genome Editing Market, by Mode, 2018-2030 (USD Million)
Table 138 Australia Genome Editing Market, by End-use, 2018-2030 (USD Million)
Table 139 Thailand Genome Editing Market, by Technology, 2018-2030 (USD Million)
Table 140 Thailand Genome Editing Market, by Delivery Method, 2018-2030 (USD Million)
Table 141 Thailand Genome Editing Market, by Application, 2018-2030 (USD Million)
Table 142 Thailand Genome Editing Market, for Genetic Engineering, by Application, 2018-2030 (USD Million)
Table 143 Thailand Genome Editing Market, for Clinical Applications, by Application, 2018-2030 (USD Million)
Table 144 Thailand Genome Editing Market, by Mode, 2018-2030 (USD Million)
Table 145 Thailand Genome Editing Market, by End-use, 2018-2030 (USD Million)
Table 146 Latin America Genome Editing Market, by Country, 2018-2030 (USD Million)
Table 147 Latin America Genome Editing Market, by Technology, 2018-2030 (USD Million)
Table 148 Latin America Genome Editing Market, by Delivery Method, 2018-2030 (USD Million)
Table 149 Latin America Genome Editing Market, by Application, 2018-2030 (USD Million)
Table 150 Latin America Genome Editing Market, for Genetic Engineering, by Application, 2018-2030 (USD Million)
Table 151 Latin America Genome Editing Market, for Clinical Applications, by Application, 2018-2030 (USD Million)
Table 152 Latin America Genome Editing Market, by Mode, 2018-2030 (USD Million)
Table 153 Latin America Genome Editing Market, by End-use, 2018-2030 (USD Million)
Table 154 Brazil Genome Editing Market, by Technology, 2018-2030 (USD Million)
Table 155 Brazil Genome Editing Market, by Delivery Method, 2018-2030 (USD Million)
Table 156 Brazil Genome Editing Market, by Application, 2018-2030 (USD Million)
Table 157 Brazil Genome Editing Market, for Genetic Engineering, by Application, 2018-2030 (USD Million)
Table 158 Brazil Genome Editing Market, for Clinical Applications, by Application, 2018-2030 (USD Million)
Table 159 Brazil Genome Editing Market, by Mode, 2018-2030 (USD Million)
Table 160 Brazil Genome Editing Market, by End-use, 2018-2030 (USD Million)
Table 161 Mexico Genome Editing Market, by Technology, 2018-2030 (USD Million)
Table 162 Mexico Genome Editing Market, by Delivery Method, 2018-2030 (USD Million)
Table 163 Mexico Genome Editing Market, by Application, 2018-2030 (USD Million)
Table 164 Mexico Genome Editing Market, for Genetic Engineering, by Application, 2018-2030 (USD Million)
Table 165 Mexico Genome Editing Market, for Clinical Applications, by Application, 2018-2030 (USD Million)
Table 166 Mexico Genome Editing Market, by Mode, 2018-2030 (USD Million)
Table 167 Mexico Genome Editing Market, by End-use, 2018-2030 (USD Million)
Table 168 Argentina Genome Editing Market, by Technology, 2018-2030 (USD Million)
Table 169 Argentina Genome Editing Market, by Delivery Method, 2018-2030 (USD Million)
Table 170 Argentina Genome Editing Market, by Application, 2018-2030 (USD Million)
Table 171 Argentina Genome Editing Market, for Genetic Engineering, by Application, 2018-2030 (USD Million)
Table 172 Argentina Genome Editing Market, for Clinical Applications, by Application, 2018-2030 (USD Million)
Table 173 Argentina Genome Editing Market, by Mode, 2018-2030 (USD Million)
Table 174 Argentina Genome Editing Market, by End-use, 2018-2030 (USD Million)
Table 175 MEA Genome Editing Market, by Country, 2018-2030 (USD Million)
Table 176 MEA Genome Editing Market, by Technology, 2018-2030 (USD Million)
Table 177 MEA Genome Editing Market, by Delivery Method, 2018-2030 (USD Million)
Table 178 MEA Genome Editing Market, by Application, 2018-2030 (USD Million)
Table 179 MEA Genome Editing Market, for Genetic Engineering, by Application, 2018-2030 (USD Million)
Table 180 MEA Genome Editing Market, for Clinical Applications, by Application, 2018-2030 (USD Million)
Table 181 MEA Genome Editing Market, by Mode, 2018-2030 (USD Million)
Table 182 MEA Genome Editing Market, by End-use, 2018-2030 (USD Million)
Table 183 South Africa Genome Editing Market, by Technology, 2018-2030 (USD Million)
Table 184 South Africa Genome Editing Market, by Delivery Method, 2018-2030 (USD Million)
Table 185 South Africa Genome Editing Market, by Application, 2018-2030 (USD Million)
Table 186 South Africa Genome Editing Market, for Genetic Engineering, by Application, 2018-2030 (USD Million)
Table 187 South Africa Genome Editing Market, for Clinical Applications, by Application, 2018-2030 (USD Million)
Table 188 South Africa Genome Editing Market, by Mode, 2018-2030 (USD Million)
Table 189 South Africa Genome Editing Market, by End-use, 2018-2030 (USD Million)
Table 190 Saudi Arabia Genome Editing Market, by Technology, 2018-2030 (USD Million)
Table 191 Saudi Arabia Genome Editing Market, by Delivery Method, 2018-2030 (USD Million)
Table 192 Saudi Arabia Genome Editing Market, by Application, 2018-2030 (USD Million)
Table 193 Saudi Arabia Genome Editing Market, for Genetic Engineering, by Application, 2018-2030 (USD Million)
Table 194 Saudi Arabia Genome Editing Market, for Clinical Applications, by Application, 2018-2030 (USD Million)
Table 195 Saudi Arabia Genome Editing Market, by Mode, 2018-2030 (USD Million)
Table 196 Saudi Arabia Genome Editing Market, by End-use, 2018-2030 (USD Million)
Table 197 UAE Genome Editing Market, by Technology, 2018-2030 (USD Million)
Table 198 UAE Genome Editing Market, by Delivery Method, 2018-2030 (USD Million)
Table 199 UAE Genome Editing Market, by Application, 2018-2030 (USD Million)
Table 200 UAE Genome Editing Market, for Genetic Engineering, by Application, 2018-2030 (USD Million)
Table 201 UAE Genome Editing Market, for Clinical Applications, by Application, 2018-2030 (USD Million)
Table 202 UAE Genome Editing Market, by Mode, 2018-2030 (USD Million)
Table 203 UAE Genome Editing Market, by End-use, 2018-2030 (USD Million)
Table 204 Kuwait Genome Editing Market, by Technology, 2018-2030 (USD Million)
Table 205 Kuwait Genome Editing Market, by Delivery Method, 2018-2030 (USD Million)
Table 206 Kuwait Genome Editing Market, by Application, 2018-2030 (USD Million)
Table 207 Kuwait Genome Editing Market, for Genetic Engineering, by Application, 2018-2030 (USD Million)
Table 208 Kuwait Genome Editing Market, for Clinical Applications, by Application, 2018-2030 (USD Million)
Table 209 Kuwait Genome Editing Market, by Mode, 2018-2030 (USD Million)
Table 210 Kuwait Genome Editing Market, by End-use, 2018-2030 (USD Million)
List of Figures
Figure 1 Genome Editing Market Segmentation
Figure 2 Data Analysis Models
Figure 3 Market Formulation and Validation
Figure 4 Data Validating & Publishing
Figure 5 Market Research Process
Figure 6 Information Procurement
Figure 7 Primary Research
Figure 8 Value-chain-based Sizing & Forecasting
Figure 9 QFD Modelling for Market Share Assessment
Figure 10 Market Formulation & Validation
Figure 11 Commodity Flow Analysis
Figure 12 Market Outlook
Figure 13 Segment Snapshot-1
Figure 14 Segment Snapshot-2
Figure 15 Segment Snapshot-3
Figure 16 Competitive Landscape Snapshot
Figure 17 Life Science Tools Market Value, 2023 (USD Billion)
Figure 18 Market Trends & Outlook
Figure 19 PESTEL Analysis
Figure 20 Porter’s Five Forces Analysis
Figure 21 Genome Editing Market: Technology Outlook Key Takeaways
Figure 22 Genome Editing Market: Technology Movement Analysis
Figure 23 CRISPR/Cas9 Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 24 TALENs/MegaTALs Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 25 ZFN Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 26 Meganucleases Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 27 Others Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 28 Genome Editing Market: Delivery Method Outlook Key Takeaways
Figure 29 Genome Editing Market: Delivery Method Movement Analysis
Figure 30 Ex-vivo Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 31 in Vivo Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 32 Genome Editing Market: Application Outlook Key Takeaways
Figure 33 Genome Editing Market: Application Movement Analysis
Figure 34 Genetic Engineering Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 35 Cell Line Engineering Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 36 Animal Genetic Engineering Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 37 Plant Genetic Engineering Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 38 Others Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 39 Clinical Applications Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 40 Diagnostics Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 41 Therapy Development Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 42 Genome Editing Market: Mode Outlook Key Takeaways
Figure 43 Genome Editing Market: Mode Movement Analysis
Figure 44 Contract Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 45 in-house Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 46 Genome Editing Market: End-use Outlook Key Takeaways
Figure 47 Genome Editing Market: End-use Movement Analysis
Figure 48 Biotechnology and Pharmaceutical Companies Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 49 Academic and Government Research Institutes Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 50 Contract Research Organizations Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 51 Regional Marketplace Outlook, 2023 & 2030 (USD Million)
Figure 52 Regional Marketplace: Key Takeaways
Figure 53 North America Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 54 U.S. Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 55 Canada Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 56 Europe Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 57 UK Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 58 Germany Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 59 France Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 60 Italy Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 61 Spain Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 62 Denmark Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 63 Sweden Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 64 Norway Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 65 Asia-Pacific Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 66 China Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 67 Japan Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 68 India Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 69 Thailand Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 70 South Korea Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 71 Australia Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 72 Latin America Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 73 Brazil Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 74 Mexico Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 75 Argentina Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 76 Middle East and Africa Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 77 South Africa Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 78 Saudi Arabia Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 79 UAE Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 80 Kuwait Market Estimates and Forecasts, 2018-2030 (USD Million)

Companies Mentioned

  • Merck KGaA
  • Cibus Inc
  • Recombinetics
  • Sangamo Therapeutics
  • Editas Medicine
  • Precision BioSciences
  • CRISPR Therapeutics
  • Intellia Therapeutics, Inc
  • Caribou Biosciences, Inc.
  • Cellectis S.A
  • AstraZeneca
  • Takara Bio Inc.
  • Horizon Discovery Ltd. (Revvity, Inc.)
  • Danaher Corporation
  • Transposagen Biopharmaceuticals, Inc.
  • Genscript Biotech Corp
  • New England Biolabs
  • OriGene Technologies, Inc.
  • bluebird bio, Inc
  • Lonza
  • Thermo Fisher Scientific, Inc.

Methodology

Loading
LOADING...

Table Information